1 rvastatin 20 mg/day, fluvastatin 40 mg/day + colestipol 20 g/day, lovastatin 80 mg/day, simvastatin 4

2 assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or c

3  with atorvastatin alone or a combination of colestipol and either atorvastatin or simvastatin for a

4 % [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively).

5 ventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels

6   In the adult mouse, dietary cholesterol or colestipol induce cholesterol 7alpha-hydroxylase mRNA le

7 ious coronary artery bypass graft surgery to colestipol/niacin plus diet or placebo plus diet.

8 tery bypass graft surgery were randomized to colestipol/niacin plus diet or placebo plus diet.

9    With all three end points, the benefit of colestipol/niacin treatment on coronary artery atheroscl

10  and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone o

11 <0.01] with lovastatin-colestipol and niacin-colestipol, respectively).

12                                   The Upjohn Colestipol Study demonstrated statistically significant

13 colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased

14       LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol

15 orvastatin required combination therapy with colestipol to achieve target LDL cholesterol concentrati

16                Treatment with lovastatin and Colestipol, which increases hepatic demands for choleste

17  of a TRPA1 antagonist or the BA sequestrant colestipol, which lowered circulating levels of BAs, pre